07:00 , Jul 30, 2015 |  BC Innovations  |  Strategy

Neglected Attention

Although the Drugs for Neglected Diseases initiative (DNDi) has made good on its 2003 promise to develop six therapies within 12 years, the not-for-profit wants to quicken the pace of progress for treatments that aren't...
08:00 , Feb 5, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Plasmodium falciparum KELCH13 mutations as markers of artemisinin resistance

Biomarkers TECHNOLOGY: Gene profiling A genomewide association study suggests mutations in Plasmodium falciparum KELCH13 could be useful as biomarkers of artemisinin resistance in the parasite. In an analysis of 1,063 patients receiving artemisinin-derived anti-malarial therapies,...
08:00 , Jan 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: P. falciparum P-type cation-transporter ATPase 4 (PfATP4)

Infectious disease INDICATION: Malaria Mouse and in vitro studies have identified a new ATPase inhibitor that could help treat malaria infections. Whole genome sequencing of mutant strains of the P. falciparum parasite resistant to the...
08:00 , Dec 19, 2013 |  BC Innovations  |  Targets & Mechanisms

Lipid kinase enters the malaria stage

A Novartis AG - University of California, San Diego -led consortium has identified a new class of antimalarials that, unlike marketed drugs, eliminates Plasmodium at all stages of its infection cycle. 1 The pharma is...
07:00 , Apr 12, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria Not applicable A study in mice identified 3-carboxyl-4(1H)-quinolone compounds that could help treat malaria. In a Plasmodium berghei mouse model of malaria, the...
08:00 , Dec 8, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria Unknown Mouse studies identified an imidazolopiperazine-based compound that could help treat malaria. In Plasmodium berghei-infected mice, a single oral dose of the imidazolopiperazine...
07:00 , Jun 6, 2011 |  BC Week In Review  |  Company News

Sanofi, Drugs for Neglected Diseases initiative deal

Sanofi partnered with the initiative to research new treatments for nine neglected tropical diseases. Sanofi will provide molecules from its libraries and the partners will jointly collaborate on research activities. Sanofi and the initiative will...
00:10 , Jun 1, 2011 |  BC Extra  |  Company News

Sanofi, DNDi in tropical disease deal

Sanofi (Euronext:SAN; NYSE:SNY) partnered with the Drugs for Neglected Diseases initiative to research new treatments for nine neglected tropical diseases. Sanofi will provide molecules from its libraries and the partners will jointly collaborate on research...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Clinical News

LIPO-102: Phase IIb data

A double-blind Phase IIb trial in 164 healthy volunteers with a body mass index (BMI) <=25 kg/m 2 showed that once-weekly subcutaneous LIPO-102 injected into the anterior abdomen for 8 weeks significantly reduced mean abdominal...
07:00 , Oct 7, 2010 |  BC Innovations  |  Cover Story

A new lead in malaria

A consortium of researchers led by the Novartis Institute for Tropical Diseases has identified a potent new class of antimalarials that could provide a much needed safeguard against parasites resistant to the largely artemisinin-based armamentarium...